Cargando…

Molecular and functional PET-fMRI measures of placebo analgesia in episodic migraine: Preliminary findings

Pain interventions with no active ingredient, placebo, are sometimes effective in treating chronic pain conditions. Prior studies on the neurobiological underpinnings of placebo analgesia indicate endogenous opioid release and changes in brain responses and functional connectivity during pain antici...

Descripción completa

Detalles Bibliográficos
Autores principales: Linnman, Clas, Catana, Ciprian, Petkov, Mike P., Chonde, Daniel Burje, Becerra, Lino, Hooker, Jacob, Borsook, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725156/
https://www.ncbi.nlm.nih.gov/pubmed/29255671
http://dx.doi.org/10.1016/j.nicl.2017.11.011
Descripción
Sumario:Pain interventions with no active ingredient, placebo, are sometimes effective in treating chronic pain conditions. Prior studies on the neurobiological underpinnings of placebo analgesia indicate endogenous opioid release and changes in brain responses and functional connectivity during pain anticipation and pain experience in healthy subjects. Here, we investigated placebo analgesia in healthy subjects and in interictal migraine patients (n = 9) and matched healthy controls (n = 9) using (11)C-diprenoprhine Positron Emission Tomography (PET) and simultaneous functional Magnetic Resonance Imaging (fMRI). Intravenous saline injections (the placebo) led to lower pain ratings, but we did not find evidence for an altered placebo response in interictal migraine subjects as compared to healthy subjects.